Nutriband (NASDAQ:NTRB – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, Zacks reports. Nutriband had a negative return on equity of 118.33% and a negative net margin of 403.98%.
Nutriband Stock Up 0.6%
Shares of NASDAQ:NTRB traded up $0.02 during mid-day trading on Thursday, reaching $3.43. 4,644 shares of the stock were exchanged, compared to its average volume of 12,155. The company has a quick ratio of 6.21, a current ratio of 6.36 and a debt-to-equity ratio of 0.01. The company has a market cap of $41.70 million, a P/E ratio of -1.32 and a beta of 1.90. Nutriband has a one year low of $3.21 and a one year high of $11.68. The stock’s 50 day simple moving average is $3.75 and its 200-day simple moving average is $4.19.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Nutriband stock. Vanguard Group Inc. lifted its position in shares of Nutriband Inc. (NASDAQ:NTRB – Free Report) by 1.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 202,738 shares of the company’s stock after purchasing an additional 3,111 shares during the period. Vanguard Group Inc. owned 1.68% of Nutriband worth $1,429,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 19.70% of the company’s stock.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on NTRB
About Nutriband
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.
Read More
- Five stocks we like better than Nutriband
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.
